唐尧生物科技
济南华维医药科技有限公司
Huawei Pharmaceutical Co. Ltd.
  • 公司概况
  • 济南华维医药科技有限公司(原上海华潍医药正式迁入山东济南药谷)是中国一流的新药筛选专业CRO公司,本公司专注于提供1.1类新药在分子水平、细胞水平、动物水平上的药效学筛选服务。

          济南华维在分子水平上可以提供的筛选服务包括,聚合ADP核糖聚合酶,酪氨酸激酶,蛋白酪氨酸磷酸酶(PTP),丝/苏氨酸激酶,组蛋白去乙酰化酶,组蛋白去甲基化酶,组蛋白甲基转移酶,DNA甲基转移酶,热休克蛋白,基质金属蛋白酶,抑制微管蛋白聚集及解聚酶,蛋白酶体,拓扑异构酶,二肽基肽酶,去乙酰化酶,过氧化物酶体增殖剂激活受体,其他与代谢相关的酶,细胞毒T淋巴细胞相关抗原4,磷酸二酯酶,磷脂酶A,调节血脂,抗病毒,抗凝血,抗高血压,溴结构域蛋白,组织蛋白酶,凋亡相关,泛素相关,β淀粉样蛋白,乙酰胆碱酯酶等,共计500余种新药靶点,涉及的疾病种类为抗肿瘤,抗糖尿病,抗炎症,免疫调节,抗病毒,心脑血管病,血液系统疾病,阿尔茨海默病等。

          济南华维在细胞水平上可以针对十几条主要的信号通路进行抑制剂的筛选,包括 cAMP/CRE/CREB通路, Hedgehog通路, JAK/STAT通路,JNK通路,. MEK/ERK通路,NF-KB通路, Notch通路, Nrf2 antioxidant通路, PI3K/AKT通路, Wnt/ catenin通路,RAR Nuclear receptor通路,TGF/SMAD通路。我公司建有较齐全的细胞库,可以针对各种正常细胞及肿瘤细胞开展细胞增殖抑制实验,细胞周期阻滞实验,细胞凋亡实验,细胞迁移实验,细胞转染及RNA干扰实验,细胞集落形成实验,针对耐药细胞株的增殖抑制实验,细胞水平的P糖蛋白底物抑制剂检测,DNA Ladder实验,基因过表达及基因沉默实验,细胞骨架免疫荧光实验,蛋白免疫印迹Western blot 实验,大鼠动脉环实验,HUVEC的管腔形成实验,活细胞水平HDAC抑制的测试,PARP的增敏细胞实验。

    济南华维拥有符合国际标准的动物饲养管理设施和现代化的功能实验室。动物饲养设施可饲养裸鼠、小鼠、大鼠、豚鼠、兔等实验动物;技术人员熟练掌握静脉注射、肌肉注射、皮下注射、腹腔注射、口服给药、经皮给药、吸入及鼻腔喷雾、滴眼及视网膜下注射等给药方式及动静脉等多种取血方式。可以对抗肿瘤药物,抗糖尿病药物及抗炎症药物,通过相应的实验动物模型进行药效学评价。

           济南华维的核心团队均具有博士学位,在大型制药企业或CRO公司从事过多年的药物筛选与开发经验,曾成功完成近百个IND的研究与申报,涵盖药物研发的多数热点领域。公司还拥有强大的顾问团队,他们均来自于药物研发的一线,能够精确把握最新的药物筛选与开发的热点技术和趋势,他们分别就职于国内外著名的科研院所、监管评审机构以及世界前十大药厂。本公司可以为客户提供最热门药物靶点相关的新药快速筛选的相关CRO服务,可以极大的提高客户进行新药筛选的实验效率,节约实验成本。        

           济南华维将以最先进的理念和最高的质量服务于客户,以缩短客户研发周期和减少客户研发成本为服务宗旨,在生物技术领域提供一如既往高品质的产品与服务,期待与您的合作!








  • 更多信息>>
  • 联系我们
  • 电 话:   15821697315 微信号: 15821697315 QQ: 1621015150
  • 0531-58990387
  • 传 真:   021-64828900
  • E-mail
  • 1621015150@qq.com
  • QQ
  • 欢迎在线咨询
  • 诺华Jakavi® (ruxolitinib)首获欧盟批准用于骨髓纤维化
  •    Novartis International AG / Novartis drug JakaviR first medication to receive European Commission approval to treat patients with myelofibrosis . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

    • JakaviR (INC424, ruxolitinib) approval based on results from the most extensive myelofibrosis clinical trial program to date
    • Myelofibrosis is a life-threatening blood cancer associated with progressive, debilitating symptoms that can severely impact quality of life and shorten survival
    • In Phase III studies, Jakavi reduced spleen size and debilitating manifestations of myelofibrosis by targeting the underlying mechanism of disease

    Basel, August 28, 2012 - Novartis received approval today from the European Commission for JakaviR (INC424, ruxolitinib), a JAK 1 and JAK 2 inhibitor for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis.

    The European Commission's decision was based on positive findings from the COMFORT (COntrolled MyeloFibrosis Study with ORal JAK Inhibitor Therapy) clinical trial program.

    "The approval of Jakavi by the European Commission brings an urgently needed new treatment option with the potential to make a real difference in patients' lives," said Dr. Claire Harrison, MD, Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London. "By targeting the dysregulated JAK pathway, Jakavi delivers a rapid and durable benefit that has the potential to become a new standard of care."

    Myelofibrosis is an uncommon, life-threatening blood cancer characterized by bone marrow failure, enlarged spleen (splenomegaly), debilitating symptoms, such as extreme fatigue, night sweats and intractable pruritus (itching), poor quality of life and weight loss, as well as shortened survival[1]. In the EU, the disease affects about 0.75 out of every 100,000 people annually[2],[3]. Myelofibrosis develops when uncontrolled signaling in the JAK pathway - which regulates blood cell production - causes bone marrow scarring and faulty blood cell production, resulting in an enlarged spleen and other severe complications. Jakavi directly targets the underlying mechanism of disease, significantly reducing splenomegaly and improving symptoms regardless of JAK mutational status, disease subtype or any prior treatment, including hydroxyurea[4],[5].

    "This approval marks a significant milestone in addressing unmet treatment needs for patients in the European Union," said Hervé Hoppenot, President, Novartis Oncology. "We are committed to the development of innovative treatments for orphan diseases, and are furthering research to assess the potential of targeted Jakavi therapy for other malignancies associated with a dysregulated JAK pathway."
                                                                                                                              
    The efficacy and safety of Jakavi in the treatment of patients with myelofibrosis was established in clinical studies, including the two pivotal Phase III trials - COMFORT-I and COMFORT-II. Chronic inflammation through elevated cytokine levels is one of the primary consequences of dysregulated JAK 1 and JAK 2 signaling, and may be a major contributor to morbidity and mortality of patients with myeloproliferative neoplasms such as myelofibrosis[6]. In one pivotal Phase III study, Jakavi was shown to alter the clinical course of myelofibrosis by reversing symptom progression and splenomegaly, thus improving quality of life and potentially impacting overall survival[4],[5].

    COMFORT-I demonstrated that 41.9% of Jakavi-treated patients achieved at least a 35% reduction (roughly equivalent to a reduction in palpable spleen size by 50%) in spleen volume at 24 weeks from baseline compared to 0.7% of patients in the placebo group (p<0.001). An early analysis of COMFORT-I data at 51 weeks of treatment showed Jakavi treatment resulted in an overall survival benefit as compared to placebo (hazard ratio=0.50 [95% confidence interval: 0.25, 0.98])[5].

    The most frequently reported grade 3 or higher adverse events were hematologic. One patient in each group discontinued treatment for thrombocytopenia or for anemia, respectively. The most common non-hematologic adverse events of any grade reported for patients receiving Jakavi or placebo, respectively, were fatigue (25% vs 34%), diarrhea (23% vs 21%), peripheral edema (19% vs 22%) and ecchymosis (19% vs 9%). One week after discontinuing Jakavi, these patients experienced a return of myelofibrosis symptoms that were present before initiating therapy; however, any symptoms they experienced as a result of treatment discontinuation subsided[5]. COMFORT-I was conducted in the US by Incyte under the worldwide collaboration and license agreement for INC424 (ruxolitinib).

    In COMFORT-II, Jakavi produced a volumetric spleen size reduction of 35% or greater in 28% of patients compared to 0% of patients in the best available therapy (BAT) group at 48 weeks (p<0.001). The BAT is any commercially available agent (such as monotherapy or in combination) or no therapy at all. At week 24, 32% of patients treated with Jakavi demonstrated a 35% or greater volumetric spleen size reduction compared to 0% of patients treated with the BAT (p<0.001) for the key secondary endpoint. Additionally, Jakavi was associated with improvements in myelofibrosis symptoms at each evaluation as compared with the BAT group. Jakavi showed modest toxicity as compared with the BAT, with increased frequency of anemia and thrombocytopenia. The most frequently reported serious adverse event (SAE) was anemia for both groups (INC424, 5%; BAT, 4%). Pneumonia was the only SAE reported in &ge;5% of patients in either group (INC424, 1%; BAT, 5%)[4]. These findings are consistent with previous investigation of INC424[7].   

    Continuous Jakavi therapy also provided a marked and durable improvement in overall quality of life measures, functioning and symptoms, including loss of appetite, dyspnea (shortness of breath), fatigue, insomnia and pain, at week 48, compared to a worsening of symptoms in BAT-treated patients. Jakavi showed modest toxicity as compared with the BAT, with increased frequency of anemia and thrombocytopenia. The most frequently reported SAE for Jakavi was anemia for both groups (5%). Pneumonia was reported in 1% of patients taking Jakavi[4].

    About Myelofibrosis
    Myelofibrosis is a life-threatening blood cancer with a poor prognosis and limited treatment options[1],[7]. Studies show that patients with myelofibrosis have a decreased life expectancy, with a median survival of 5.7 years[8]. Although allogeneic stem cell transplantation may cure myelofibrosis, the procedure is associated with significant morbidity and transplant-related mortalityand is available to less than 5% of patients who are young and fit enough to undergo the procedure[9].

    About Jakavi 
    JakaviR (INC424, ruxolitinib) is an oral inhibitor of the JAK 1 and JAK 2 tyrosine kinases[4]. The recommended starting dose for Jakavi is 15 mg twice daily for patients with a platelet count between 100,000cubic millimeters (mm3) and 200,000 mm3,and 20 mg twice daily for patients with a platelet count of >200,000 mm3. Doses may be titrated based on safety and efficacy.

    Novartis licensed INC424 (ruxolitinib) from Incyte for development and potential commercialization outside the US. Incyte has retained rights for the development and commercialization of INC424 (ruxolitinib) in the US. Both the European Commission and the US Food and Drug Administration (FDA) granted INC424 (ruxolitinib) orphan drug status for myelofibrosis. Incyte received FDA approval for INC424 (ruxolitinib) in November 2011 under the name JakafiR for the treatment of patients with intermediate or high-risk myelofibrosis. 

    As part of the Novartis clinical development program, Jakavi is also being investigated in clinical trials for the treatment of polycythemia vera[10]. 

    Jakavi is a registered trademark of Novartis AG in countries outside the United States. 

    JakaviR Important Safety Information
    JakaviR can cause serious side effects, including a decrease in blood cell count and infections. Complete blood count monitoring is recommended. Dose reduction or interruption may be required in patients with severe hepatic or renal impairment or in patients developing hematologic adverse reactions such as thrombocytopenia, anemia and neutropenia. Dose reductions are also recommended when Jakavi is co-administered with strong CYP3A4 inhibitors or fluconazole. Use of Jakavi during pregnancy is not recommended and women should avoid becoming pregnant during Jakavi therapy. Women taking Jakavi should not breast feed.

    The most common adverse drug reactions (incidence >10%) are urinary tract infections, anemia, thrombocytopenia, neutropenia, hypercholesterolaemia, dizziness, headache, alanine aminotransaminase increased, asparte aminotransferase increased, bruising, bleeding and increased blood pressure. Other common adverse drug reactions (incidence 1 to 10%) are herpes zoster, weight gain, flatulence and tuberculosis.

    Disclaimer
    The foregoing release contains forward-looking statements that can be identified by terminology such as "potential," "committed," "potentially," "being investigated," or similar expressions, or by express or implied discussions regarding potential additional marketing approvals for Jakavi, or regarding the potential approval of new indications or labeling for Jakavi, and the timing of any such approvals, or regarding potential future revenues from Jakavi. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with Jakavi to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Jakavi will be approved for sale in any additional markets, or for any additional indications or labeling, or at any particular time. Neither can there be any guarantee that Jakavi will achieve any particular levels of revenue in the future. In particular, management's expectations regarding Jakavi could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; government, industry and general public pricing pressures; unexpected manufacturing issues; competition in general; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

    About Novartis
    Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2011, the Group achieved net sales of USD 58.6 billion, while approximately USD 9.6 billion (USD 9.2 billion excluding impairment and amortization charges) was invested in R&D throughout the Group. Novartis Group companies employ approximately 126,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.

    Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis.

    References
    [1] Mesa RA, Schwagera S, Radia D, et al. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res. 2009;33:1199-1203.
    [2] Girodon F, Bonicelli G, Schaeffer C, et al. Significant increase in the apparent incidence of essential thrombocythemia related to new WHO diagnostic criteria: a population-based study. Haematologica. 2009; 94(6):865-869.
    [3] McNally RJQ, Rowland D, Roman E, Cartwright RA. Age and sex distributions of hematological malignancies in the U.K. Hematol Oncol. 1997;15:173-189.
    [4] Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis. New Eng J Med. 2012: March 1;366:787-98.
    [5] Verstovsek S, Mesa RA, Gotlib J, et al. A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis. New Eng J Med. 2012: March 1;366:799-807.
    [6] Hasselbach, H. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2012. Epub ahead of print February 7.
    [7] Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and Efficacy of JAK1 & JAK2 Inhibitor, INCB018424, in Myelofibrosis. New Eng J Med. 2010 September 16;363:1117-1127.
    [8] Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113:2895-2901.
    [9] Patriarca F, Bacigalupo A, Sperotto A, et al. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Haematologica. 2008;93(10):1514-1522.
    [10] National Institutes of Health. Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor JAKAVI (INCB018424) Tablets Versus Best Available Care: The RESPONSE Trial. Available at http://www.clinicaltrials.gov/ct2/show/NCT01243944?term=ruxolitinib&rank=14. Accessed January 31, 2012.

  • 关闭  打印 登出时间 2013-09-17
  • 地址:山东省济南市高新区港兴三路济南药谷1号楼A座2508
  • 电话:15821697315 微信号: 15821697315 QQ: 1621015150 / 0531-58990387   传真:021-64828900
  • Powered by TANG 3.6 Copyright @ 2012 - 2015 唐尧生物